$2.02 0.5%
CRON Stock Price vs. AI Score
Data gathered: December 4

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Cronos Group (CRON)

Analysis generated November 20, 2024. Powered by Chat GPT.

Cronos Group, a globally recognized player in the cannabis industry, aims to build disruptive intellectual property by advancing cannabis research, technology, and product development. The company's diverse international presence and strategic partnerships underscore its strong market positioning. Cronos operates through a network of geographic regions, offering a wide range of products geared towards both medical and recreational users. The innovation-driven approach sets Cronos apart, but market competition, regulatory landscapes, and industry fluctuations remain critical factors to monitor.

Read full AI stock Analysis

Stock Alerts - Cronos Group (CRON)

company logo Cronos Group | November 26
Business Outlook among employees is up by 8.3% over the last month.
company logo Cronos Group | November 25
Price is up by 5.1% in the last 24h.
company logo Cronos Group | November 13
Price is down by -5.1% in the last 24h.
company logo Cronos Group | November 12
Price is up by 5.6% in the last 24h.

About Cronos Group

Cronos Group is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development.


Cronos Group
Price $2.02
Target Price Sign up
Volume 1,170,000
Market Cap $797M
Year Range $1.97 - $3.02
Dividend Yield 0%
Analyst Rating 0% buy
Industry Medical Cannabis

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2485M45M3.6M8.3M-33M0.000
Q2 '2472M31M6.3M-8.8M-15M-0.020
Q1 '2474M27M4.5M-2.2M-15M-0.010
Q4 '2347M30M1.9M-45M-21M-0.050
Q3 '2367M31M4M-1.6M-20M-0.004

Insider Transactions View All

ADLER JASON MARC filed to buy 601,016 shares at $1.7.
June 1 '23
ADLER JASON MARC filed to buy 1,402,304 shares at $1.7.
June 1 '23
ADLER JASON MARC filed to buy 589,766 shares at $1.8.
May 30 '23
ADLER JASON MARC filed to buy 1,376,054 shares at $1.8.
May 30 '23
ADLER JASON MARC filed to buy 559,765 shares at $1.9.
May 25 '23

What is the Market Cap of Cronos Group?

The Market Cap of Cronos Group is $797M.

What is the current stock price of Cronos Group?

Currently, the price of one share of Cronos Group stock is $2.02.

How can I analyze the CRON stock price chart for investment decisions?

The CRON stock price chart above provides a comprehensive visual representation of Cronos Group's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cronos Group shares. Our platform offers an up-to-date CRON stock price chart, along with technical data analysis and alternative data insights.

Does CRON offer dividends to its shareholders?

As of our latest update, Cronos Group (CRON) does not offer dividends to its shareholders. Investors interested in Cronos Group should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Cronos Group?

Some of the similar stocks of Cronos Group are Tilray, Canopy Growth, Aurora Cannabis, Sundial Growers, and Organigram.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.